Is Q/C TECHNOLOGIES, INC. (QCLS) Halal?

NASDAQ Technology United States $27M
✓ HALAL
Confidence: 83/100
Q/C TECHNOLOGIES, INC. (QCLS) is Halal under 3 of 5 Shariah screening standards, including AAOIFI Standard 21. With a debt ratio of just 0.0% against the AAOIFI threshold of 30%, Q/C TECHNOLOGIES, INC. comfortably passes the key financial ratio tests. The company operates in the Technology sector (Computer Hardware), which is not a prohibited industry under Islamic finance principles.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 0.0%
/ 30%
24.1%
/ 30%
0.0%
/ 30%
N/A ✓ HALAL
DJIM 0.0%
/ 33%
24.1%
/ 33%
0.0%
/ 33%
N/A ✓ HALAL
MSCI 0.0%
/ 33%
39.8%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
S&P 0.0%
/ 33%
24.1%
/ 33%
0.0%
/ 33%
N/A ✓ HALAL
FTSE 0.0%
/ 33%
39.8%
/ 33%
0.0%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-114.59
P/B Ratio
0.7
Revenue
$0
Beta
2.2
High volatility
Current Ratio
1.7

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
Return on Equity (ROE) -40.6%
Return on Assets (ROA) -16.4%

Cash Flow & Balance Sheet

Operating Cash Flow-$9M
Free Cash Flow-$9M
Total Debt$10,579
Current Ratio1.7
Total Assets$21M

Price & Trading

Last Close$3.53
50-Day MA$4.00
200-Day MA$6.12
Avg Volume1.2M
Beta2.2
52-Week Range
$2.50
$44.40

About Q/C TECHNOLOGIES, INC. (QCLS)

CEO
Mr. Joshua N. Silverman
Employees
2
Sector
Technology
Industry
Computer Hardware
Country
United States
Exchange
NASDAQ
Market Cap
$27M
Currency
USD

Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. The company also develops a silicon photonic computing architecture for AI inference. The company has a strategic alliance with DADA2 Foundation for research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.

Related Halal Stocks in Technology

Frequently Asked Questions

Is Q/C TECHNOLOGIES, INC. (QCLS) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Q/C TECHNOLOGIES, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Q/C TECHNOLOGIES, INC.'s debt ratio?

Q/C TECHNOLOGIES, INC.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.

What are Q/C TECHNOLOGIES, INC.'s key financial metrics?

Q/C TECHNOLOGIES, INC. has a market capitalization of $27M. Return on equity stands at -40.6%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.